# Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine

> **NCT03303105** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 50 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** TEV-48125
- **DRUG:** TEV-48125

## Key facts

- **NCT ID:** NCT03303105
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-07
- **Primary completion:** 2020-06-16
- **Final completion:** 2020-06-16
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03303105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03303105, "Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03303105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*